Ignite Creation Date:
2024-05-05 @ 12:09 PM
Last Modification Date:
2024-10-26 @ 9:20 AM
Study NCT ID:
NCT00250770
Status:
WITHDRAWN
Last Update Posted:
2023-07-05
First Post:
2005-11-04
Brief Title:
Colony-Stimulating Factor-1 CSF-1 and Other Cytokines in Human Endometrial Carcinogenesis
Sponsor:
University of New Mexico
Organization:
University of New Mexico
Study Overview
Official Title:
CSF-1 and Other Cytokines in Human Endometrial Carcinogenesis
Status:
WITHDRAWN
Status Verified Date:
2023-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purposes of this study are the following
1 To further characterize and quantify both CSF-1 and colony-stimulating factor-1 receptor CSF-1R expression from additional tumor specimens specifically tumors of high grade and from metastatic sites
2 To assay using Enzyme-Linked ImmunoSorbent Assay ELISA sandwich monoclonal antibody methodology CSF-1 expression in the peritoneal fluid and blood from patients with endometrial adenocarcinomas
3 Using immunohistochemistry to evaluate the presence of staining for CSF-1 and CSF-1R from additional patients with endometrial adenocarcinomas especially of high grades and from metastatic sites
4 To determine the extent of cytokine specifically CSF-1 but also interleukin-1 IL-1 IL-6 and granulocyte-macrophage colony-stimulating factor GM-CSF production in endometrial carcinoma cells in primary cell culture
5 To determine the responsiveness of epithelial cells on estrogen and antiestrogen binding to determine if CSF-1 production is mediated in these cells by estrogen receptor binding or alternative pathways of intracellularcell-cell signal transduction
6 The ultimate objective of these experiments is to characterize CSF-1 expression from benign and tumor cells in order to identify steps in the CSF-1 activated signalling pathways that may represent potential targets for therapy
1 To further characterize and quantify both CSF-1 and colony-stimulating factor-1 receptor CSF-1R expression from additional tumor specimens specifically tumors of high grade and from metastatic sites
2 To assay using Enzyme-Linked ImmunoSorbent Assay ELISA sandwich monoclonal antibody methodology CSF-1 expression in the peritoneal fluid and blood from patients with endometrial adenocarcinomas
3 Using immunohistochemistry to evaluate the presence of staining for CSF-1 and CSF-1R from additional patients with endometrial adenocarcinomas especially of high grades and from metastatic sites
4 To determine the extent of cytokine specifically CSF-1 but also interleukin-1 IL-1 IL-6 and granulocyte-macrophage colony-stimulating factor GM-CSF production in endometrial carcinoma cells in primary cell culture
5 To determine the responsiveness of epithelial cells on estrogen and antiestrogen binding to determine if CSF-1 production is mediated in these cells by estrogen receptor binding or alternative pathways of intracellularcell-cell signal transduction
6 The ultimate objective of these experiments is to characterize CSF-1 expression from benign and tumor cells in order to identify steps in the CSF-1 activated signalling pathways that may represent potential targets for therapy
Detailed Description:
These experiments taken together should critically determine if there is a role for the CSF-1 c-fms autocrine endocrine or paracrine loop in the progression of endometrial adenocarcinoma If so alterations in this loop may provide novel medical therapies for this disease Additionally these experiments will determine which are the predominant cytokines expressed in these tumors and will help the investigators to determine the role if any these cytokines play in cancer cell growth and proliferation in relationship with each other and within and outside of the estrogen-mediated pathways
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None